falsefalse

ESMO 2024: Treatment of uHCC - Episode 11

Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

, , , , ,

Panelists discuss the CELESTIAL trial findings and their implications for second-line treatment strategies in Japan for patients with previously treated hepatocellular carcinoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)
    EP. 2: Treatment Decisions Based on BLCL Stage
    EP. 3: Current Treatment in First Line – IO + TKI or IO + IO
    EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line
    EP. 5: EMERALD-1 Study Results
    EP. 6: Discussion and Summary
    EP. 7: LEAP-012 Study Results
    EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing
    EP. 9: ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient
    EP. 10: Choosing Second-Line Therapies: Considering First Line Therapy Received
    Now Viewing
    EP. 11: Discussion of CELESTIAL Trial and Second-Line Treatment in Japan
    EP. 12: CELESTIAL Sub-Group Discussion
    EP. 13: Discussion of RESORCE Trial
    EP. 14: Real-World Treatment Data from the Phase 4 STELLAR Trial
    EP. 15: Importance of Real-World Data in Supporting Treatment Options
    EP. 16: CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment
    EP. 17: Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs

    Video content above is prompted by the following:

    Dr Alese: Please discuss the data surrounding about treatment with cabozantinib for previously treated hepatocellular carcinomaHCC from the CELESTIAL trial.
    • Primary trial results – (Abou-Alfa G, et al. N Eng J Med. 2018)
    • Child-Pugh class B subgroup analysis – (El-Khoueiry AB, et al. BMC Cancer. 2022)
    • Prior immuno-oncologyIO subgroup analysis – (Wong JSL, et al. J Clin Oncol. 2021)

    Related Content:

    ESMO 2024: Treatment of uHCC
    Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs
    CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment
    Importance of Real-World Data in Supporting Treatment Options
    x